Neovacs SA (FR:ALNEV)
:ALNEV
Top Page
Neovacs SA
(ALNEV)
Select Model
Select Model
Rating:37Underperform
Price Target:
<€0.01
▼(-10.00% Downside)
Action:DowngradedDate:12/05/25
Neovacs SA's overall stock score is significantly impacted by its poor financial performance, characterized by declining revenues and negative profit margins. The technical analysis further supports a bearish outlook with oversold conditions. The lack of earnings and dividend yield reflects a weak valuation, contributing to the low overall score.
Positive Factors
Proprietary Kinoid platform
Owning the Kinoid immunotherapy platform is a durable strategic asset: it can be applied across multiple autoimmune indications, reduces single-product risk, and supports long-term licensing or co-development deals, strengthening future revenue diversification.
Negative Factors
Declining revenues and negative margins
Sustained revenue decline and persistently negative margins indicate weak commercial traction and poor operational scalability. Over time this undermines ability to fund trials, attract partners on favorable terms, and makes reaching sustained profitability a material structural challenge.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Kinoid platform
Owning the Kinoid immunotherapy platform is a durable strategic asset: it can be applied across multiple autoimmune indications, reduces single-product risk, and supports long-term licensing or co-development deals, strengthening future revenue diversification.
Read all positive factors
Neovacs SA (ALNEV) vs. iShares MSCI France ETF (EWQ)
Market Cap
€196.17K
Dividend YieldN/A
Average Volume (3M)1.46M
Price to Earnings (P/E)―
Beta (1Y)1.54
Revenue Growth-45.39%
EPS Growth99.99%
CountryFR
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,449,000
10 Day Avg. Volume1,456,964
30 Day Avg. Volume1,459,251
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)9.86
Price to Sales (P/S)485.89
P/FCF Ratio-48.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neovacs SA Business Overview & Revenue Model
Company Description
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory disease...
How the Company Makes Money
Neovacs generates revenue primarily through the development and commercialization of its therapeutic candidates. The company focuses on securing partnerships and collaborations with larger pharmaceutical companies for the development and marketing...
Neovacs SA Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 366.35K | 533.41K | 1.11K | 22.59K | 29.78K |
| Gross Profit | 42.42K | -6.75M | -6.26M | -7.60M | -3.39M |
| EBITDA | -6.61M | -8.45M | -3.61M | -10.38M | -4.63M |
| Net Income | -32.91M | -8.74M | -3.55M | -11.84M | -6.14M |
Balance Sheet | |||||
| Total Assets | 22.07M | 47.53M | 49.28M | 48.55M | 13.49M |
| Cash, Cash Equivalents and Short-Term Investments | 435.45K | 887.09K | 6.76M | 33.09M | 10.07M |
| Total Debt | 230.37K | 650.59K | 1.20M | 1.03M | 388.36K |
| Total Liabilities | 4.01M | 3.71M | 5.05M | 4.65M | 2.50M |
| Stockholders Equity | 18.06M | 43.82M | 44.23M | 43.90M | 10.98M |
Cash Flow | |||||
| Free Cash Flow | -3.68M | -2.12M | -4.60M | -10.26M | -5.86M |
| Operating Cash Flow | -3.60M | -1.91M | -4.45M | -9.91M | -5.65M |
| Investing Cash Flow | 1.45M | -11.08M | -31.56M | -18.81M | -222.71K |
| Financing Cash Flow | 1.70M | 6.79M | 9.99M | 51.75M | 14.65M |
Neovacs SA Technical Analysis
Negative
0.01
Price Trends
0.05
Negative
0.31
Negative
Market Momentum
-0.02
Negative
27.04
Positive
3.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALNEV, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.05, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 27.04 is Positive, neither overbought nor oversold. The STOCH value of 3.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALNEV.
Neovacs SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | €44.47M | -2.27 | ― | ― | ― | 10.30% | |
47 Neutral | €6.67M | -0.90 | -876.63% | ― | ― | ― | |
42 Neutral | €1.51M | -0.18 | 92.02% | ― | ― | ― | |
37 Underperform | €196.17K | ― | ― | ― | -45.39% | 99.99% |
* Healthcare Sector Average
FR:ALNEV
Neovacs SA
0.01
-33.09
-99.97%
FR:ALQGC
Quantum Genomics Societe Anonyme
0.07
0.00
0.00%
FR:ALTAO
Hybrigenics SA Class A
0.01
0.00
0.00%
FR:ALTME
TME Pharma N.V.
0.07
<0.01
4.48%
FR:ALBPS
Biophytis SA
0.02
-0.17
-91.58%
FR:ALTHX
Theranexus SA
3.08
2.69
685.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.